Physician profile
Jennifer S Kim
NPI 1790748473
$16,221.08
in general payments reported to CMS, 2019-2025
11 companies · $13K in 2025
The $13K reported for 2025 was more than what 88% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2021: $61.20 · 2022: $121 · 2023: $2,115 · 2024: $287 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,100 · Consulting Fee: $6,100 · Travel and Lodging: $1,923 · Food and Beverage: $914 · Honoraria: $175 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,100.00 |
| Consulting Fee | $6,100.00 |
| Travel and Lodging | $1,922.65 |
| Food and Beverage | $914.23 |
| Honoraria | $175.00 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $14,442.34 | 2023-2025 | Auvi-Q |
| Glaxosmithkline, LLC. | $824.46 | 2019-2022 | |
| Ethicon US, LLC | $376.01 | 2023-2025 | N/A, Proximate, Megadyne |
| Aimmune Therapeutics, INC. | $175.00 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $111.54 | 2024 | Airsupra |
| Blueprint Medicines Corporation | $106.99 | 2025 | Ayvakit |
| Mylan Pharmaceuticals INC. | $63.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.04 | 2021-2022 | |
| Agile Therapeutics, INC. | $40.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2023 | Dupixent |
| Channel Medsystems, INC. | $17.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.